ClinicalTrials.Veeva

Menu

NOTIFY (New Observations Taking Information From Yesterday)

Stanford University logo

Stanford University

Status

Begins enrollment this month

Conditions

Atherosclerotic Cardiovascular Disease

Treatments

Other: Clinician Guideline Reminder
Other: CAC Notification

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

This trial will investigate whether notifying patients and their clinicians of the presence of moderate or severe coronary artery calcium on a low-dose CT scan performed for lung cancer screening results in a lower incidence of death, nonfatal myocardial infarction, or nonfatal stroke as compared with practice guideline reminders.

Enrollment

40,000 estimated patients

Sex

All

Ages

50 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >=18 years
  • No known ASCVD
  • Lung cancer screenee with low dose CT scan (LDCT) within the last 5 years
  • Coronary artery calcium (CAC) score on LDCT >100 Agatston units (AU)
  • Not taking a statin or other lipid-lowering therapy (e.g., ezetimibe, bempedoic acid, or PCSK9-lowering therapy)

Exclusion criteria

  • Dementia or other neuropsychiatric disorder that interferes with medication adherence
  • CAC scan, coronary CT angiogram, or invasive angiogram since LDCT
  • Statin medication intolerance or allergy
  • Life expectancy <2 years, e.g., metastatic cancer or active cancer undergoing chemotherapy

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

40,000 participants in 2 patient groups

Patient-Clinician CAC Notification
Experimental group
Description:
The CAC Notification intervention sent to both patients and clinicians has five features. 1) Results of a high CAC score (\>100 AU) detected on the patient's prior chest CT, 2) an image of the patient's CAC clearly marked, 3) a recommendation to have a patient-clinician risk discussion, 4) specific statin dosing recommended by guidelines, and 5) a link to the prevention gidelines.
Treatment:
Other: CAC Notification
Clinician Guideline Reminder
Other group
Description:
The Guideline Reminder intervention sent to primary care clinicians has five features. 1) A reminder that all patients should have their 10-year risk for ASCVD events calculated, 2) a figure of the recommended treatment algorithm according to ASCVD 10-year risk, 3) a nudge that patients who qualify for lung cancer screening are generally at high ASCVD risk, 4) a reminder that patients at elevated risk should be engaged in shared decision-making to discuss statin therapy and other preventive interventions, and 5) access to the complete ACC/AHA Primary Prevention Guidelines and the online 10-year ASCVD risk estimator.
Treatment:
Other: Clinician Guideline Reminder

Trial contacts and locations

0

Loading...

Central trial contact

David J Maron, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems